Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will
hold a conference call to discuss final Phase 2b PROMISE kidney
transplant data for the Company's lead immunosuppressive drug,
voclosporin, on Wednesday, June 4th at 9:00 a.m. ET/7:00 a.m. MT.

As previously announced, the final Phase 2b kidney transplant
trial (PROMISE) results will be presented during an oral presentation
by Dr. Osama Gaber, Director of Transplantation, Vice-Chair for
Administration and Faculty Affairs, Department of Surgery, The
Methodist Hospital, Cornell University in New York at the 2008
American Transplant Congress in Toronto, Ontario. Dr. Gaber, as one
of the principal investigators in the PROMISE trial, will present
detailed data including the primary endpoint as determined by biopsy
proven acute rejection and relevant safety data. Dr. Gaber's
presentation is scheduled to take place on Tuesday, June 3 at 4:50
p.m. ET.

All interested parties will be able to access the live event
(listen only mode) through the Company's corporate web site at
http://www.isotechnika.com and access the replay at +1-416-640-1917
or +1-877-289-8525 using the pass code, 21273673.

About Isotechnika Inc.
----------------------

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are designed to offer
advantages over other currently available treatments. There is a
significant unmet medical need in the treatment of both solid organ
transplantation and autoimmune disease. It is estimated that the
market potential will exceed CAD$4 billion annually in sales for
calcineurin inhibitors such as voclosporin by 2010.

Voclosporin is a next generation calcineurin inhibitor, which
recently completed a Phase 2b North American trial for the prevention
of kidney rejection following transplantation. An extension to the
Phase 2b trial and a combined Phase 3 European/Canadian trial for the
treatment of moderate to severe psoriasis are ongoing. Our partner,
Lux Biosciences, is currently conducting three separate Phase 2/3
pivotal trials investigating voclosporin (referred to as LX211 by
Lux) for the treatment of uveitis. Voclosporin has been approved to
enter First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner,
Atrium Medical Corporation.

Isotechnika Inc. is a publicly traded company on the Toronto
Stock Exchange under the symbol "ISA". More information on
Isotechnika can be found at http://www.isotechnika.com.

Forward-Looking Statements
--------------------------

This press release may contain forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, events
or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Forward-looking statements, including the Company's
belief as to the potential of its products, the Company's
expectations regarding the issuance of additional patents and the
Company's ability to protect its intellectual property, involve known
and unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others,
securing and maintaining corporate alliances, the need for additional
capital and the effect of capital market conditions and other factors
on capital availability, the ability to economically manufacture its
products, the potential of its products, the success and timely
completion of clinical studies and trials, the Company's ability to
successfully commercialize its products, competition, the ability of
the Company to defend its patents from infringement by third parties,
and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Additional risks and
uncertainties relating to the Company and its business can be found
in the "Risk Factors" section of the Company's Annual Information
Form. These factors should be considered carefully and readers are
cautioned not to place undue reliance on such forward-looking
statements.

For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com